NCT01607294View on ClinicalTrials.gov

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
HyperlipidemiaType 2 Diabetes
Interventions
DRUG

ETC-1002

ETC-1002 Daily for 4 weeks

DRUG

Placebo

Placebo Daily for 4 weeks

Trial Locations (1)

Unknown

Miramar

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY

NCT01607294 - A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter